Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press12310.17650/2220-3478-2015-1-37-42REVIEWОБЗОРЫ ЛИТЕРАТУРЫCHOICE OF TARGETED DRUG FOR SECOND-LINE METASTATIC COLON CANCER CHEMOTHERAPYВЫБОР ТАРГЕТНОГО ПРЕПАРАТА ВО ВТОРОЙ ЛИНИИ ТЕРАПИИ БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ ТОЛСТОЙ КИШКИFedyaninM. Yu.ФедянинМ. Ю.
Russian Federation

N.N. Blokhin Russian Cancer Research Center; 24 Kashirskoye Shosse, Moscow, 115478, Russia

ФГБНУ «РОНЦ им. Н.Н. Блохина»; Россия, 115478, Москва, Каширское шоссе, 24

 

 

fedianinmu@mail.ruTryakinA. A.ТрякинА. А.
Russian Federation

N.N. Blokhin Russian Cancer Research Center; 24 Kashirskoye Shosse, Moscow, 115478, Russia

ФГБНУ «РОНЦ им. Н.Н. Блохина»; Россия, 115478, Москва, Каширское шоссе, 24

TjulandinS. A.ТюляндинС. А.
Russian Federation

N.N. Blokhin Russian Cancer Research Center; 24 Kashirskoye Shosse, Moscow, 115478, Russia

ФГБНУ «РОНЦ им. Н.Н. Блохина»; Россия, 115478, Москва, Каширское шоссе, 24

N.N. Blokhin Russian Cancer Research CenterФГБНУ «РОНЦ им. Н.Н. Блохина»260520155137422605201526052015Copyright ©; 2015, ABV-pressCopyright ©; 2015, АБВ-пресс2015ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/123

During the last 5 years the prognosis of metastatic colorectal cancer patients improved significantly. This results not only from increased amount of surgery for metastatic disease and use of targeted drugs in first-line treatment, but also from increased number of patients receiving effective second- and third-line chemotherapy. Currently a minimum of 7 treatment groups can be distinguished depending on prior first-line chemo- and targeted therapy. Consequentially we have less evidence-based data to guide the treatment choice for next treatment lines. This article discusses the choice of targeted drugs in combination with second-line chemotherapy.

За последние 5 лет значимо выросла выживаемость больных метастатическим раком толстой кишки (мРТК). Это обусловлено не только активным внедрением хирургического удаления метастазов и применением таргетных препаратов в 1-й линии терапии, но и тем, что все большему числу пациентов проводится 2-я и последующие линии эффективного системного лечения. В настоящее время внедрение новых таргетных препаратов в 1-й линии терапии привело к формированию как минимум 7 ле- чебных групп в зависимости от того, что получал пациент в 1-й линии. Поэтому, если ориентироваться на постулаты доказательной медицины, стало труднее определиться с наиболее эффективным лечением во 2-й линии в каждой данной группе больных. Именно сложности выбора таргетных препаратов во 2-й линии терапии у больных с мРТК и посвящен настоящий обзор.

metastatic colon cancersecond-line chemotherapytargeted therapyметастатический рак толстой кишкивторая линия химиотерапиитаргетная терапия1. Tournigand С., André T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2):229–37.Tournigand С., André T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2):229–37.2. Grothey A., Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005 Dec 20;23(36):9441–2.Grothey A., Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005 Dec 20;23(36):9441–2.3. Schmoll H.J., Van Cutsem E., Stein A. et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012 Oct;23(10): 2479–516.Schmoll H.J., Van Cutsem E., Stein A. et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012 Oct;23(10): 2479–516.4. Giantonio B.J., Catalano P.J., Meropol N.J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007 Apr 20;25(12):1539–44.Giantonio B.J., Catalano P.J., Meropol N.J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007 Apr 20;25(12):1539–44.5. Tamagawa H., Iwamoto S., Takahashi T. et al. FOLFIRI plus bevacizumab (bev) as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) who have failed first-line bev plus oxaliplatin based therapy: The randomized phase III EAGLE study. JCO suppl. ASCO 2013, abs 3516.Tamagawa H., Iwamoto S., Takahashi T. et al. FOLFIRI plus bevacizumab (bev) as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) who have failed first-line bev plus oxaliplatin based therapy: The randomized phase III EAGLE study. JCO suppl. ASCO 2013, abs 3516.6. Hong Y.S., Kim H.J., Park S.J. et al. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. Cancer Sci 2013 Apr;104(4):473–80.Hong Y.S., Kim H.J., Park S.J. et al. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. Cancer Sci 2013 Apr;104(4):473–80.7. Sobrero A.F., Maurel J., Fehrenbacher L. et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008 May 10;26(14):2311–9.Sobrero A.F., Maurel J., Fehrenbacher L. et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008 May 10;26(14):2311–9.8. Seymour M.T., Brown S.R., Middleton G. et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild- type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013 Jul;14(8):749–59.Seymour M.T., Brown S.R., Middleton G. et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild- type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013 Jul;14(8):749–59.9. Peeters M., Price T.J., Cervantes A. et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second- line treatment of metastatic colorectal cancer. Ann Oncol 2014 Jan;25(1):107–16.Peeters M., Price T.J., Cervantes A. et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second- line treatment of metastatic colorectal cancer. Ann Oncol 2014 Jan;25(1):107–16.10. Peeters M., Oliner K.S., Price T.J. et al. Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32:5s (suppl; abstr 3568).Peeters M., Oliner K.S., Price T.J. et al. Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32:5s (suppl; abstr 3568).11. Élez E., Kocáková I., Höhler T. et al. Abituzumab combined with cetuximab plus irinotecan as second-line treatment for patients with KRAS wild-type metastatic colorectal cancer: The POSEIDON phase I trial/ randomized phase II trial. Ann Oncol 2014;25(suppl 4):iv167–209.Élez E., Kocáková I., Höhler T. et al. Abituzumab combined with cetuximab plus irinotecan as second-line treatment for patients with KRAS wild-type metastatic colorectal cancer: The POSEIDON phase I trial/ randomized phase II trial. Ann Oncol 2014;25(suppl 4):iv167–209.12. Beretta G.D., Petrelli F., Stinco S. et al. FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials. Med Oncol 2013 Mar;30(1):486.Beretta G.D., Petrelli F., Stinco S. et al. FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials. Med Oncol 2013 Mar;30(1):486.13. Van Cutsem E., Dicato M., Geva R. et al. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 2011 Jun; 22 Suppl 5:v1–9.Van Cutsem E., Dicato M., Geva R. et al. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 2011 Jun; 22 Suppl 5:v1–9.14. Chau I., Joulain F., Iqbal S.U., Bridgewater J. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer 2014;14:605. doi: 10.1186/1471-2407-14-605.Chau I., Joulain F., Iqbal S.U., Bridgewater J. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer 2014;14:605. doi: 10.1186/1471-2407-14-605.15. Pericay C., Folprecht G., Saunders M. et al. Phase 2 randomized, noncomparative open-label study of aflibercept and modified FOLFOX6 in the first line treatment of metastatic colorectal cancer (AFFIRM). Ann Oncol 2012;23(Suppl 4):iv16, abstr. 0024.Pericay C., Folprecht G., Saunders M. et al. Phase 2 randomized, noncomparative open-label study of aflibercept and modified FOLFOX6 in the first line treatment of metastatic colorectal cancer (AFFIRM). Ann Oncol 2012;23(Suppl 4):iv16, abstr. 0024.16. Grothey A., Sugrue M.M., Purdie D.M. et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008 Nov 20;26(33):5326–34.Grothey A., Sugrue M.M., Purdie D.M. et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008 Nov 20;26(33):5326–34.17. Bendell J.C., Bekaii-Saab T.S., Cohn A.L. et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 2012;17(12):1486–95.Bendell J.C., Bekaii-Saab T.S., Cohn A.L. et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 2012;17(12):1486–95.18. Bennouna J., Sastre J., Arnold D. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013 Jan;14(1):29–37.Bennouna J., Sastre J., Arnold D. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013 Jan;14(1):29–37.19. Masi G., Loupakis F., Salvatore L. et al. Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO). J Clin Oncol 2013;31:15 (suppl; abstr 3615).Masi G., Loupakis F., Salvatore L. et al. Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO). J Clin Oncol 2013;31:15 (suppl; abstr 3615).20. Kopetz S., Hoff P.M., Morris J.S. et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010 Jan 20;28(3):453–9.Kopetz S., Hoff P.M., Morris J.S. et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010 Jan 20;28(3):453–9.21. Loupakis F., Cremolini C., Fioravanti A. et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011 Apr 12;104(8):1262–9.Loupakis F., Cremolini C., Fioravanti A. et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011 Apr 12;104(8):1262–9.22. Masi G., Loupakis F., Salvatore L. et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first- line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845–52.Masi G., Loupakis F., Salvatore L. et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first- line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845–52.23. Tabernero J., Cohn A.L., Obermannova R. et al. RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J Clin Oncol 2015;33(suppl 3; abstr 512).Tabernero J., Cohn A.L., Obermannova R. et al. RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J Clin Oncol 2015;33(suppl 3; abstr 512).24. Heinemann V., von Weikersthal L.F., Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065–75.Heinemann V., von Weikersthal L.F., Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065–75.25. Modest D.P., Stintzing S., von Weikersthal L.F. et al. Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial. J Clin Oncol 2014;32:5s (suppl; abstr 3558^).Modest D.P., Stintzing S., von Weikersthal L.F. et al. Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial. J Clin Oncol 2014;32:5s (suppl; abstr 3558^).26. Rivera F., Schwartzberg L.S., Karthaus M. et al. Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32:5s (suppl; abstr 3629).Rivera F., Schwartzberg L.S., Karthaus M. et al. Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32:5s (suppl; abstr 3629).